{"publication_id":"98a3a091-c5b2-412b-a3c6-744963f23cb2","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}